Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750MGlobeNewsWire • 01/11/23
Sanofi SA (SNY) CEO Paul Hudson Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/10/23
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology ProgramsBusiness Wire • 01/10/23
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infantsGlobeNewsWire • 01/05/23
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of MedicineGlobeNewsWire • 12/21/22
MHRA authorises VidPrevtyn® Beta▼ in Great Britain, Sanofi's COVID-19 booster vaccineBusiness Wire • 12/21/22
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncologyGlobeNewsWire • 12/19/22
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in OncologyBusiness Wire • 12/19/22
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitisGlobeNewsWire • 12/16/22
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularisGlobeNewsWire • 12/15/22
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%Investors Business Daily • 12/14/22